Tech Company Financing Transactions
Kriya Therapeutics Funding Round
On 7/15/2021, Kriya Therapeutics received $100 million in Series B funding from Patient Square Capital, Amplo and AVG Ventures.
Transaction Overview
Company Name
Announced On
7/15/2021
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to further develop Kriya's core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1100 Island Dr. 203
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Undisclosed
Website
Email Address
Overview
The era of gene therapy has arrived. Our mission at Kriya Therapeutics is to expand the reach of gene therapy to address highly prevalent and serious diseases affecting millions of patients. Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Roger Jeffs
Chief Executive Officer
Shankar Ramaswamy
Chief Financial Officer
Daniel Chen
Chief Medical Officer
Ilise Lombardo
Chief Technical Officer
Nachi Gupta
Co-Founder
Fraser Wright
Controller
Amy Chen
Vice President
Ashlyn Bassiri
Vice President
Erik Hughes
Vice President
Mitch Lower
Vice President
Jason Mallory
Vice President
Zhu Pirot
Vice President
Joseph Rabinowitz
Vice President
Stephen Soltys
Vice President
Michele Stone
Vice President
Wayne Yount
VP - Administration
Lily Nguyen
VP - Bus. Development
Melissa Rhodes
VP - General Counsel
Dana Johnson
VP - Manufacturing
Britt Petty
VP - Regulatory Affairs
Harold Alterson
VP - Regulatory Affairs
Brian Furmanski
Browse more venture capital transactions:
Prev: 7/15/2021: MOBILion Systems venture capital transaction
Next: 7/15/2021: Ribon Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs